In Vivo Gene Editing Patents

In vivo gene editing patents cover systemic-delivery/LNP innovations; targeted/extrahepatic-delivery innovations; editing-durability innovations; and off-target/safety and cargo innovations — with IP held by gene-editing companies (in a field editing genes directly inside the patient's body). WHY IN VIVO GENE EDITING: gene editing can be done EX VIVO (remove a patient's cells, edit them in a lab, reinfuse — complex, expensive, per-patient) or IN VIVO (inject the gene editor so it travels to and edits cells IN PLACE inside the body); IN-VIVO editing is far SIMPLER, more scalable, and cheaper — potentially a one-time injection that corrects a disease — but the central challenge is DELIVERY: getting the editor (CRISPR-Cas + guide) into ENOUGH of the RIGHT cells, SAFELY, since off-target edits in the body can't be screened out as in ex-vivo manufacturing. MAJOR HOLDERS: INTELLIA THERAPEUTICS (NTLA-2001 — the first systemic in-vivo CRISPR therapy, for ATTR amyloidosis; NTLA-2002 for HAE), plus BEAM, VERVE (in-vivo base editing), EDITAS, and CRISPR THERAPEUTICS. Systemic/LNP delivery, targeted/extrahepatic delivery, editing durability, off-target/safety, and editor cargo are the core in-vivo-editing patent domains — and systemic delivery, extrahepatic targeting, safety, and re-dosing are the open whitespace.

Systemic-delivery/LNP innovations; targeted/extrahepatic-delivery innovations; cargo/editor-format innovations; and dosing/biodistribution innovations represent core in-vivo-editing patent domains — and getting the editor to the right cells (the central problem) is where most of the value and IP concentrate. SYSTEMIC-DELIVERY / LNP PATENTS: delivering the gene editor through the BLOODSTREAM — typically LIPID NANOPARTICLES (LNPs) carrying CRISPR-Cas mRNA + guide RNA, which naturally accumulate in the LIVER (the proven route — Intellia NTLA-2001 edits the liver to lower a disease protein); LNP compositions, lipid chemistry, and mRNA/guide cargo formulation are core, high-value IP (delivery IS the in-vivo editing problem — and the liver is the first solved organ). TARGETED / EXTRAHEPATIC-DELIVERY PATENTS: the NEXT FRONTIER — reaching cells BEYOND the liver (muscle, CNS/brain, lung, bone marrow, immune cells, eye), since LNPs default to liver and most diseases are elsewhere; targeting LIGANDS, engineered LNPs (selective organ targeting), AAV, and other vectors for tissue-specific delivery are high-value, open whitespace IP (extrahepatic in-vivo editing unlocks vastly more diseases — the biggest opportunity). CARGO / EDITOR-FORMAT PATENTS: WHAT is delivered — Cas9 NUCLEASE (for knockout) vs base/prime editors (for precise correction) delivered in vivo, mRNA vs RNP vs DNA format, and size/packaging constraints; cargo/format methods are high-value. DOSING / BIODISTRIBUTION PATENTS: dose, biodistribution, and reaching enough cells; dosing methods are valuable. Systemic LNP delivery, extrahepatic targeting, cargo format, and dosing are the highest-value core IP because delivering the editor efficiently and selectively to the right cells is exactly the central, value-determining problem of in-vivo editing.

Editing-durability innovations; off-target/safety innovations; re-dosing/immunity innovations; and indication and manufacturing innovations represent additional in-vivo-editing patent domains — and the permanence of edits, the unfixable safety risk, and re-administration are where in-vivo editing's unique advantages and risks live. EDITING-DURABILITY PATENTS: a key advantage — in-vivo edits are PERMANENT in the cells that get edited (a one-time injection can produce a durable, even lifelong effect — e.g., permanently lowering a harmful protein), so reaching enough cells once can be curative; methods maximizing durable editing (and editing the right, long-lived cells) are high-value IP (one-and-done durability is in-vivo editing's promise). OFF-TARGET / SAFETY PATENTS: a critical, unique risk — unlike ex-vivo (where edited cells can be screened before reinfusion), in-vivo edits happen in the body and CANNOT be undone or screened out, so OFF-TARGET edits, on-target unintended outcomes, and immune reactions to the editor are serious; high-specificity editors, off-target prediction/screening, controlled/transient editor exposure, and safety methods are CRITICAL, high-value IP (safety is paramount and a key differentiator). RE-DOSING / IMMUNITY PATENTS: the body may develop IMMUNITY to the editor (Cas protein) or vector, limiting RE-DOSING (a problem if one dose doesn't edit enough cells); methods enabling re-administration or sufficient single-dose editing are valuable. INDICATION / MANUFACTURING PATENTS: specific in-vivo indications (liver diseases first — ATTR, HAE; then expanding) and editor/LNP manufacturing; indication and manufacturing methods are valuable. Editing durability, off-target safety, re-dosing, and indications are the highest-value application IP because durable, SAFE, sufficient in-vivo editing against the right diseases is exactly what makes in-vivo editing a one-time cure rather than a risk.

In vivo gene editing startup IP strategy must navigate the CRISPR-Cas9 tool IP layer (Broad/UC — foundational editor patents sit beneath any in-vivo product), the LNP-delivery IP (overlapping with mRNA-vaccine LNP patents — a dense, contested thicket), Intellia/Beam/Verve/Editas portfolios, the delivery-is-everything reality (in-vivo editing's value and IP are dominated by delivery), the liver-vs-extrahepatic split (liver is solved/crowded; extrahepatic is the biggest whitespace), the off-target/safety imperative (unfixable in-body edits make safety paramount), the editing-tool + delivery + base/prime-editor stacked licensing, the heavy clinical/FDA path, and a landscape where systemic delivery, extrahepatic targeting, safety, durability, and re-dosing are the durable assets; understand that the CRISPR tool and liver-LNP are foundationally/heavily patented, so the durable IP for newcomers is in EXTRAHEPATIC/targeted delivery, novel LNPs/vectors, high-specificity safety, re-dosing, and specific indications — with delivery innovation often the real differentiator (and a stacked licensing reality), and that delivery reach, safety/specificity, durable efficacy, and FTO across the stack matter as much as patents; identify whitespace in extrahepatic delivery, safety, and re-dosing. IN-VIVO-EDITING STARTUP IP STRATEGY: DELIVERY IS EVERYTHING — EXTRAHEPATIC/TARGETED DELIVERY, NOVEL LNPs/VECTORS, SAFETY, DURABILITY, AND RE-DOSING ARE THE IP: patent extrahepatic/targeted delivery, novel LNP/vector compositions, high-specificity safety, durability, and re-dosing methods; THE STACKED LICENSING REALITY IS CENTRAL: CRISPR-Cas9 tool IP (Broad/UC), LNP-delivery IP (mRNA-vaccine thicket), and base/prime-editor IP all sit beneath an in-vivo product — plan to license multiple layers AND clear your delivery IP; EXTRAHEPATIC/TARGETED DELIVERY IS THE BIGGEST WHITESPACE: liver (LNP) is solved/crowded (Intellia) — reaching muscle/CNS/lung/immune cells via targeting ligands/engineered LNPs/AAV is the major opportunity and most-valuable new IP (it unlocks most diseases); DELIVERY (LNP/VECTOR) COMPOSITIONS ARE CORE: lipid chemistry, targeting, and cargo formulation are the heart of in-vivo editing IP; OFF-TARGET/SAFETY IS PARAMOUNT (UNFIXABLE IN-BODY): in-vivo edits can't be screened/undone — high-specificity editors, controlled exposure, and safety methods are critical, defensible IP; DURABILITY IS THE PROMISE (ONE-AND-DONE): permanent, sufficient single-dose editing of the right cells is in-vivo editing's value — durability methods are high-value; RE-DOSING/IMMUNITY IS A REAL LIMIT AND WHITESPACE: enabling re-administration (or one-dose sufficiency) addresses a key constraint; INDICATIONS START IN LIVER, EXPAND OUT: liver diseases (ATTR/HAE) first; new tissues/indications are valuable; DELIVERY-REACH/SAFETY/DURABILITY/FTO MATTER AS MUCH AS PATENTS: delivery reach, safety/specificity, durable efficacy, and freedom across the stacked IP drive value; WHEN TO PATENT: NOVEL DELIVERY/SAFETY/DURABILITY/RE-DOSING WITH MEASURED DATA: file once a method shows measured results (editing efficiency in target tissue + delivery/biodistribution + off-target/specificity + durability + safety + (extrahepatic) tissue reach) — measured target-tissue editing, delivery reach (esp. extrahepatic), specificity/safety, and durability are the critical in-vivo-editing IP metrics; KEY FTO CHECKLIST: CRISPR-Cas9 tool (Broad/UC); LNP delivery (mRNA-vaccine LNP thicket); Intellia NTLA-2001/2002; Beam/Verve in-vivo base editing; Editas/CRISPR-Tx; systemic LNP (CRISPR mRNA + guide, liver) delivery/lipid chemistry; targeted/extrahepatic delivery (ligands/engineered LNP/AAV — muscle/CNS/lung/immune); cargo/editor format (Cas9 nuclease vs base/prime; mRNA/RNP); editing durability/cell-type; off-target/specificity/controlled exposure/safety; re-dosing/anti-editor immunity; indications (liver first, expanding); manufacturing; FDA/clinical path.